Inhalation Sciences appoints new Chief Commercial Officer to drive global sales

Inhalation Sciences (ISAB) has appointed Paolo Raffaelli as its new Chief Commercial Officer (CCO). Mr Raffaelli has extensive experience driving international sales in a wide range of medical device companies and takes up his position on December 14, 2020.

The new CCO will be responsible for driving ISAB sales in Europe, the US and other international markets. He will have overall responsibility for Sales and Marketing activities, with a primary focus on account targeting.

Paolo Raffaelli has over 20 years’ executive experience in the life science and medical device industry, with extensive sales and marketing management experience, across European and international markets and he has been based in Stockholm, Brussels and the US. Paolo has a degree in computer science from La Sapienza University in Rome, and an MBA from IMD Business School in Lausanne, Switzerland.  

ISAB CEO Manoush Masarrat: “We are excited to welcome Paolo to the team. His outstanding record in European, US and global sales management will add enormous value. 2020 has been a year of increased sales and profit for us. In 2021 our strategic goal is to drive this momentum forward as we become clear leaders in our field. Paolo is a fantastic asset in helping us achieve this.”

Paolo Raffaelli: “I am very excited about the positive impact Inhalation Sciences can make for our customers’ drug development process, de-risking their clinical trials already in the pre-clinical phase. PreciseInhale clearly offers the possibility to get pre-clinical research right the first time.”

For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153